Filing Details

Accession Number:
0001209191-21-028259
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-26 16:03:22
Reporting Period:
2021-04-22
Accepted Time:
2021-04-26 16:03:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434316 Fate Therapeutics Inc FATE Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1586893 Scott J Wolchko C/O Fate Therapeutics, Inc.;
3535 General Atomics Court #200
San Diego CA 92121
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-22 30,000 $2.73 423,793 No 4 M Direct
Common Stock Disposition 2021-04-22 30,000 $85.54 393,793 No 4 S Direct
Common Stock Acquisiton 2021-04-23 10,000 $2.73 403,793 No 4 M Direct
Common Stock Acquisiton 2021-04-23 14,846 $6.62 418,639 No 4 M Direct
Common Stock Acquisiton 2021-04-23 5,154 $4.84 423,793 No 4 M Direct
Common Stock Disposition 2021-04-23 30,000 $85.24 393,793 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-04-22 30,000 $0.00 30,000 $2.73
Common Stock Stock Option (right to buy) Disposition 2021-04-23 10,000 $0.00 10,000 $2.73
Common Stock Stock Option (right to buy) Disposition 2021-04-23 14,846 $0.00 14,846 $6.62
Common Stock Stock Option (right to buy) Disposition 2021-04-23 5,154 $0.00 5,154 $4.84
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
140,000 2027-01-03 No 4 M Direct
130,000 2027-01-03 No 4 M Direct
0 2024-01-08 No 4 M Direct
64,846 2025-01-04 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.
  2. This option is fully vested.
  3. Not applicable.